Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Strategy/Bus Ops Officer

Chief Executive Officer

Chief Medical Officer

Chief Scientific Officer

Chief Financial Officer

See Remarks

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting gen...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-11	Premium	sold	Premium	Premium	Premium	Chief Strategy/Bus Ops Officer
2023-08-17	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2023-08-17	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2023-08-16	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-08-16	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-05-26	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2023-02-17	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2023-02-17	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2023-02-17	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2022-10-25	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-10-25	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2022-09-16	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-09-13	Premium	gifted	Premium	Premium	Premium	-
2022-09-12	Premium	acquired	Premium	Premium	Premium	-
2022-08-11	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2022-05-25	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2022-02-10	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2022-02-10	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2021-12-14	Premium	gifted	Premium	Premium	Premium	-
2021-12-09	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2021-08-20	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-08-09	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2020-10-27	Premium	bought	Premium	Premium	Premium	-
2020-10-27	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer
2020-10-27	Premium	acquired	Premium	Premium	Premium	See Remarks

FHTX - Foghorn Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for FHTX